Table 2.

Incidence of hepatocellular carcinoma and death and transplantation.

	Hepatocellular carcinoma				Death and transplantation
	ETV (n = 180)	TDF (n = 224)	IRR (95% CI)	P	ETV (n = 180)	TDF (n = 224)	IRR (95% CI)	P
1 year
Cumulative incidence	1	0			0	0
CIR (95% CI), per 100 PY	0.58 (0.03‒2.55)	0.00 (0.00‒0.00)	‒	0.27	0.00 (0.00‒0.00)	0.00 (0.00‒0.00)	‒	‒
3 years
Cumulative incidence	7	5			1	2
CIR (95% CI), per 100 PY	1.53 (0.66‒2.95)	0.85 (0.30‒1.82)	1.81 (0.57‒5.69)	0.31	0.21 (0.01‒0.90)	0.32 (0.05‒0.97)	0.65 (0.06‒7.20)	0.73
5 years
Cumulative incidence	15	6			2	2
CIR (95% CI), per 100 PY	2.28 (1.31‒3.63)	0.74 (0.29‒1.50)	3.08 (1.19‒7.93)	0.014	0.28 (0.05‒0.86)	0.23 (0.04‒0.70)	1.23 (0.17‒8.74)	0.83
Total period
Cumulative incidence	18	6			4	2
CIR (95% CI), per 100 PY	2.19 (1.33‒3.36)	0.71 (0.28‒1.44)	3.07 (1.22‒7.74)	0.012	0.45 (0.14‒1.05)	0.23 (0.04‒0.70)	1.99 (0.37‒10.88)	0.42

ETV entecavir, TDF tenofovir disoproxil fumarate, CIR cumulative incidence rate, IRR incidence rate ratio, CI confidence interval, PY person-years.